All In Biotech

Drug Trial Radar · NCT05814939

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

Last checked: Nov 19, 2026Latest source record: Jul 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Apr 26, 2023

Primary completion

May 11, 2024

Study completion May 11, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.

Conditions

  • Active Ankylosing Spondylitis

Interventions

  • VC005 tabletsDrug

    VC005 groups repeat administration for 12 weeks

  • Tofacitinib Citrate TabletsDrug

    Tofacitinib Citrate groups repeat administration for 12 weeks

  • VC005 Tablets PlaceboDrug

    VC005 placebo groups repeat administration for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients achieving ASAS20Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.